Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1

Conditions

Sarcoma 1Lymphoma 1Carcinoma 1

Interventions

pembrolizumab 3temsirolimus 1spartalizumab 1poly ICLC 1patritumab 1durvalumab 1atezolizumab 1advexin 1Tetanus Toxoid 1Sunitinib 1Rifampin 1Radiation 1Nivolumab 1Midazolam 1Ketoconazole 1Ipilimumab 1Interleukin-15 1Brentuximab Vedotin 1Blood Specimen Collection 1Axitinib 13-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione 12,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid 11-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × patritumab × Lymphoid × Clear all
NCT01479023 2013-12-20

Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors

Washington University School of Medicine

Phase 1 Terminated
12 enrolled
LymphoidSarcoma

Carcinoma, Lymphoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡